Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.

ABSTRACT:

Importance

It is currently unclear whether chronic kidney disease (CKD)-associated cardiovascular risk in type 2 diabetes (T2D) is modifiable.

Objective

To examine whether cardiovascular risk can be modified with finerenone in patients with T2D and CKD.

Design, setting, and participants

Incidence rates from Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis (FIDELITY), a pooled analysis of 2 phase 3 trials (including patients with CKD and T2D randomly assigned to receive finerenone or placebo) were combined with National Health and Nutrition Examination Survey data to simulate the number of composite cardiovascular events that may be prevented per year with finerenone at a population level. Data were

SUBMITTER: Agarwal R 

PROVIDER: S-EPMC10267848 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature